The expression of BIRC5 is correlated with loss of specific chromosomal regions in breast carcinomas

Genes Chromosomes and Cancer

Volumn 47, Issue 4, 2008, Pages 299-308

  Boidot, Romain ^a   Vegran, Frédérique ^a,b   Jacob, Delphine ^a   Chevrier, Sandy ^a   Gangneux, Nicolas ^a   Taboureau, Johann ^a   Oudin, Claire ^a   Rainville, Vinciane ^a   Mercier, Liliane ^a   Lizard Nacol, Sarab ^a  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b University of Medical School   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DEMETHYLASE; ENZYME; SURVIVIN; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BIRC5 GENE; BREAST CARCINOMA; CELL PROLIFERATION; CELL STRAIN MCF 7; CHROMOSOMAL REGION LOSS; CHROMOSOMES AND CHROMOSOMAL PHENOMENA; CONTROLLED STUDY; GENE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 40049100299     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20533     Document Type: Article

References (29)

1. Altieri DC, Marchisio PC. 1999. BIRC5 apoptosis: An interloper between cell death and cell proliferation in cancer. Lab Invest 79: 1327–1333.
2. Ambrosini G, Adida C, Altieri DC. 1997. A novel anti‐apoptosis gene, BIRC5, expressed in cancer and lymphoma. Nat Med 3: 917–921.
3. Ambrosini G, Adida C, Sirugo G, Altieri DC. 1998. Induction of apoptosis and inhibition of cell proliferation by BIRC5 gene targeting. J Biol Chem 273: 11177–11182.
4. Arnal M, Franco N, Fargeot P, Riedinger JM, Brunet‐Lecomte P, Lizard‐Nacol S. 2000. Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer. Breast Cancer Res Treat 61: 13–20.
5. Blum R, Elkon R, Yaari S, Zundelevich A, Jacob‐Hirsch J, Rechavi G, Shamir R, Kloog Y. 2007. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S‐farnesylthiosalicylic acid). Cancer Res 67: 3320–3328.
6. Carboni GL, Gao B, Nishizaki M, Xu K, Minna JD, Roth JA, Ji L. 2003. CACNA2D2‐mediated apoptosis in NSCLC cells is associated with alterations of the intracellular calcium signaling and disruption of mitochondria membrane integrity. Oncogene 22: 615–626.
7. Chomczynski P, Sacchi N. 1987. Single‐step method of RNA isolation by acid guanidinium thiocyanate‐phenol‐chloroform extraction. Anal Biochem 162: 156–159.
8. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. 2000. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25: 315–319.
9. Dammann R, Yang G, Pfeifer GP. 2001. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 61: 3105–3109.
10. Endoh T, Tsuji N, Asanuma K, Yagihashi A, Watanabe N. 2005. BIRC5 enhances telomerase activity via up‐regulation of specificity protein‐1 and c‐Myc‐mediated human telomerase reverse transcriptase gene transcription. Exp Cell Res 305: 300–311.
11. Franco N, Picard SF, Mege F, Arnould L, Lizard‐Nacol S. 2001. Absence of genetic abnormalities in fibroadenomas of the breast determined at p53 gene mutations and microsatellite alterations. Cancer Res 61: 7955–7958.
12. Greer CE, Wheeler CM, Manos MM. 1995. PCR amplification from paraffin‐embedded tissues. In: Dieffenbach CW, Dvksler GS, editors. PCR Primer. A Laboratory Manual. New York: Cold Spring Harbor Laboratory Press, pp. 99–111.
13. Hattori M, Sakamoto H, Satoh K, Yamamoto T. 2001. DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c‐erbB‐2 and BIRC5 genes. Cancer Lett 169: 155–164.
14. Hesson LB, Cooper WN, Latif F. 2007. Evaluation of the 3p21.3 tumour‐suppressor gene cluster. Oncogene 26: 7283–7301.
15. Kondo M, Ji L, Kamibayashi C, Tomizawa Y, Randle D, Sekido Y, Yokota J, Kashuba V, Zabarovsky E, Kuzmin I, Lerman M, Roth J, Minna JD. 2001. Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells. Oncogene 20: 6258–62562.
16. Li F. 2003. BIRC5 study: What is the next wave? J Cell Physiol 197: 8–29.
17. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real‐time quantitative PCR and the 2(‐Delta Delta C(T)) Method. Methods 25: 402–408.
18. Ohtani S, Iwamaru A, Deng W, Ueda K, Wu G, Jayachandran G, Kondo S, Atkinson EN, Minna JD, Roth JA, Ji L. 2007. Tumor suppressor 101F6 and ascorbate synergistically and selectively inhibit non‐small cell lung cancer growth by caspase‐independent apoptosis and autophagy. Cancer Res 67: 6293–6303.
19. Rai SK, Duh FM, Vigdorovich V, Danilkovitch‐Miagkova A, Lerman MI, Miller AD. 2001. Candidate tumor suppressor HYAL2 is a glycosylphosphatidylinositol (GPI)‐anchored cell‐surface receptor for jaagsiekte sheep retrovirus, the envelope protein of which mediates oncogenic transformation. Proc Natl Acad Sci USA 98: 4443–4448.
20. Rieder MJ, Livingston RJ, Daniels MR, Chung MW, Miyamoto KE, Nguyen CP. 2003. NIEHPS‐SNPs, Environmental Genome Project, NIEHS ES15478, Department of Genome.
21. Senchenko VN, Liu J, Loginov W, Bazov I, Angeloni D, Seryogin Y, Ermilova V, Kazubskaya T, Garkavtseva R, Zabarovska VI, Kashuba VI, Kisselev LL, Minna JD, Lerman MI, Klein G, Braga EA, Zabarovsky ER. 2004. Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas. Oncogene 23: 5719–5728.
22. Shen CY, Yu JC, Lo YL, Kuo CH, Yue CT, Jou YS, Huang CS, Lung JC, Wu CW. 2000. Genome‐wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinomas: An implication for mutator phenotype and breast cancer pathogenesis. Cancer Res 60: 3884–3892.
23. Sommer KW, Schamberger CJ, Schmidt GE, Sasgary S, Cerni C. 2003. Inhibitor of apoptosis protein (IAP) BIRC5 is upregulated by oncogenic c‐H‐Ras. Oncogene 22: 4266–4280.
24. Tajiri T, Tanaka S, Shono K, Kinoshita Y, Fujii Y, Suita S, Ihara K, Hara T. 2001. Quick quantitative analysis of gene dosages associated with prognosis in neuroblastoma. Cancer Lett 166: 89–94.
25. Végran F, Boidot R, Oudin C, Riedinger JM, Lizard‐Nacol S. 2005. Distinct expression of BIRC5 splice variants in breast carcinomas. Int J Oncol 27: 1151–1157.
26. Végran F, Boidot R, Oudin C, Defrain C, Rebucci M, Lizard‐Nacol S. 2007. Association of p53 gene alterations with the expression of antiapoptotic BIRC5 splice variants in breast cancer. Oncogene 26: 290–297.
27. Vos MD, Ellis CA, Bell A, Birrer MJ, Clark GJ. 2000. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem 275: 35669–35672.
28. Xu Y, Fang F, Ludewig G, Jones G, Jones D. 2004. A mutation found in the promoter region of the human BIRC5 gene is correlated to overexpression of BIRC5 in cancer cells. DNA Cell Biol 23: 527–537.
29. Yau WL, Lung HL, Zabarovsky ER, Lerman MI, Sham JS, Chua DT, Tsao SW, Stanbridge EJ, Lung ML. 2006. Functional studies of the chromosome 3p21.3 candidate tumor suppressor gene BLU/ZMYND10 in nasopharyngeal carcinoma. Int J Cancer 119: 2821–2826.